Hormone Therapy: It's Time for a Second Opinion
Author(s): Collins Joseph J, Ahlgrimm Maria
Issue: Mar/Apr 2008 - Compounding Around the World
View All Articles in Issue
Page(s): 122-127
Download in electronic PDF format for $75
Abstract: The opinion paper titled “Compounded Bioidentical Hormones,” published by the American College of Obstetricians and Gynecologists in November 2005, appears to be aimed at influencing how some clinicians care for their patients. The paper may not accurately report the findings of authors listed in its own references in regard to safety and efficacy of bioidentical hormones, nor does it address the fact that a number of mass-produced preparations on the market include bioidentical estradiol, progesterone, and/or testosterone. The authors of the paper take the point of view that hormone therapy does not belong to a class of drugs with an indication for individualized dosing, but this position is not congruent with the fact that manufacturers of mass-produced hormones have U.S. Food and Drug Administration approval when they discuss flexible dosing of bioidentical hormones. The opinion paper openly opposes compounded bioidentical hormones, yet fails to mention the legal precedence and regulatory oversights that s
Related Keywords: Joseph J. Collins, RN, ND, Marla Ahlgrimm, RPh, bioidentical hormone replacement therapy, drug safety, US Food and Drug Administration, serum hormone levels, salivary hormone levels, saliva testing, American College of Obstetricians and Gynecologists, ACOG opinion paper, menopause, personalized medicine, estrogen, estradiol, information resources
Related Categories: HRT, LEGAL, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, LITERATURE REVIEW, PROFESSIONAL ISSUES